Strengthening ATMP Development in Europe: How Global Supply Chain and BioServices Centers in France Enable Efficiency and Scalability

As Advanced Therapy Medicinal Product (ATMP) developers progress from early-stage research to late-phase clinical trials and commercialization, biostorage, sample management, and regulatory-compliant logistics become increasingly complex. Efficiently managing these critical components is essential to ensure product integrity, regulatory compliance, and seamless supply chain operations.

Expanding Integrated ATMP Supply Chain Hub in Paris

In late 2025, Cryoport Systems launched the cornerstone of its integrated European infrastructure, a state-of-the-art Global Supply Chain Center in the greater Paris region. This facility strengthens ATMP development across Europe with comprehensive temperature-controlled logistics and advanced shipping systems under one roof, and the company plans to expand offerings even further to include BioServices (biostorage, kit production, drug packaging and labeling) and IntegriCell™ cryopreservation in the near future. As the demand for ATMPs grow, Cryoport Systems continues to meet evolving industry needs, expanding its European infrastructure to support scalability and operational efficiency through specialized supply chain solutions for early development through global commercialization.

Supporting Biopharma Innovation Across Europe

Cryoport Systems’ Global Supply Chain Center in Paris is strategically located near Aéroport de Paris-Charles de Gaulle for optimal regional access and distribution. The supply chain hub includes a wholly owned fleet of Cryoport Systems’ proprietary shipping systems, which are custom engineered to support sensitive biological materials. It also offers 24-hour global dispatch capability, consulting and advisory support, and quality oversight in alignment with the company’s global network, going beyond logistics to support every stage of the product lifecycle. The Global Supply Chain Center is designed to meet complex client needs, compliantly handling sensitive materials and delivering clients’ therapies safely and efficiently.

Managing ATMP Supply Chains Goes Beyond Logistics

ATMP developers often face significant hurdles beyond transportation and temperature-controlled shipping. These include:

• Biostorage Limitations: Many ATMP developers lack access to GMP-compliant, temperature-controlled biorepositories to securely store cell and gene therapy materials, research materials, and clinical samples.
• Regulatory & QP Oversight: European regulations require Qualified Person (QP) services for importation, storage, and distribution of ATMPs, adding complexity to supply chain planning.
• Sample Management & Processing: Clinical trials generate large volumes of patient samples requiring centralized processing, testing, and long-term storage to meet regulatory and study requirements.
• End-to-End Compliance: A fragmented supply chain can create gaps in chain of custody, data integrity, and regulatory documentation, leading to delays or compliance risks.

Without a fully integrated, end-to-end supply chain solution, ATMP developers risk inefficiencies that could slow down clinical progress or compromise the viability of patient-specific materials.

Providing Comprehensive Suite of Solutions in France

To address these challenges, Cryoport Systems’ Global Supply Chain Center and BioServices Centers in France provide a comprehensive suite of solutions that extend beyond logistics to support every stage of ATMP development:

GMP-Compliant Biostorage & Sample Management

• Secure, temperature-controlled storage for research, clinical, and commercial materials.
• Centralized clinical sample management, including inventory tracking and real-time monitoring.
• Pre-analytical sample processing, including PBMC isolation, aliquoting, and plasma/serum extraction.

Regulatory & QP Services

• QP oversight for importation, release, and distribution of ATMP materials.
• Compliance with European Medicines Agency (EMA) regulations and GMP standards.
• End-to-end regulatory documentation and trade compliance support.

Clinical Trial Support & Custom Kitting

• Patient sample processing, testing, and centralized management to streamline clinical workflows.
• Custom kit production for sample collection, ensuring standardization and compliance.
• Packaging, labeling, and distribution for clinical and commercial ATMP shipments.

With these capabilities, Cryoport Systems ensures that ATMP developers have the infrastructure and expertise to scale operations efficiently without compromising compliance or product integrity.

Establishing Strategic Hub for ATMP Development

France is a rapidly expanding hub for biopharmaceutical research, manufacturing, and clinical development. With its strong regulatory framework, skilled workforce, and growing investment in ATMPs, France provides an ideal location for centralized logistics and BioServices that support European and global clinical programs.

Cryoport Systems’ Global Supply Chain Center in Paris and BioServices Centers in Clermont-Ferrand and Pont-du-Château serve as key infrastructure for biopharma companies, CDMOs, and clinical research organizations seeking end-to-end solutions that streamline ATMP supply chains.

Enabling the Future of ATMPs with Integrated Supply Chain

A successful ATMP supply chain requires more than just logistics, it demands a fully integrated biostorage, regulatory, and sample management strategy to maintain compliance and ensure product integrity. Cryoport Systems’ Global Supply Chain Center and BioServices Centers in France provide a seamless supply chain solution, allowing developers to focus on advancing therapies rather than managing supply chain complexities.

For ATMP sponsors, clinical teams, and CDMOs looking to scale their operations in Europe, Cryoport Systems offers the infrastructure and expertise needed to ensure certainty and compliance from clinical trials to commercialization.